FusionPlex® Dx and LiquidPlex™ Dx
Invitae’s Anchored Multiplex PCR (AMP™) chemistry is now available as a CE-marked in-vitro diagnostic (IVD) test for your lab in the European Union, enabling broader patient access to the right cancer therapies at the right time.
This ready-validated, next-generation sequencing kit can enable quick and actionable insights with superior gene fusion detection by RNA analysis, while also solving for tissue insufficiency issues with ctDNA analysis. The results can help ensure that patients are quickly matched to the most effective therapies for their unique solid tumor type, even for those with rare or novel gene fusions.
NOT APPROVED BY THE FDA. ONLY AVAILABLE IN THE EUROPEAN UNION.
Actionable Insights for NSCLC and Solid Tumors
Expert-curated, pre-established content for cost-effective, targeted testing of actionable biomarkers. Provide your patients with broader therapy options and optimal clinical trial enrollment.
Superior Gene Fusion Detection for Better Therapy Selection
AMP-powered RNA sequencing assays detect both known and novel gene fusions and can help you identify more patients who may be eligible for fusion-directed therapies.
Comprehensive Genomic Profiling
Get the most information from your low-input FFPE or liquid biopsy sample. Detect gene fusions, single-nucleotide variants (SNVs), and insertions and deletions (indels).
Streamlined Workflow for Rapid Decision Making
All Invitae panels powered by AMP chemistry follow the same simple workflow for maximum efficiency. Ensure more patients are quickly matched to the most effective therapies for their unique solid tumor type.
Comprehensive results in a single run. Minimal sample requirements circumvent insufficient or inadequate tissue samples and ensure broader patient access to testing.
GDPR compliant software
FusionPlex Dx and LiquidPlex Dx analysis software meets requirements for GDPR compliance, and can be deployed in regional data centers.